Versant V Luxco S.a r.l. 3
Accession 0001140361-19-017854
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 6:05 PM ET
Size
18.4 KB
Accession
0001140361-19-017854
Insider Transaction Report
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)- 12,670
Common Stock
- 12,670
Common Stock
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)
- 12,670
Common Stock
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)- 12,670
Common Stock
- 12,670
Common Stock
Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)- 12,670
Common Stock
Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)- 12,670
Common Stock
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)
- 12,670
Common Stock
Series B Convertible Preferred Stock
→ Common Stock (1,993,658 underlying)Series C Convertible Preferred Stock
→ Common Stock (512,995 underlying)
Footnotes (2)
- [F1]Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
- [F2]These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") will automatically be converted into shares of the Issuer's Common Stock, on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock has no expiration date.
Documents
Issuer
Aprea Therapeutics, Inc.
CIK 0001781983
Related Parties
1- filerCIK 0001786141
Filing Metadata
- Form type
- 3
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 6:05 PM ET
- Size
- 18.4 KB